COMMON AND IRREVERSIBLE
structural heart defect
Mitral regurgitation is a chronic, irreversible heart condition that affects an estimated 8 million people in the US and Europe.
Of those, about 2 million suffer from moderate to severe (grade 3-4) functional regurgitation: the valve leaflets are intact but too far apart due to the dilation of the heart, a common feature of heart failure. At that stage, life expectancy is usually less than 7 years.
Some medical devices can be used to bring the leaflets closer together (edge-to-edge) using a minimally invasive procedure. Unfortunately, today few patients (<5%) are eligible for this approach.
Thus, the unmet medical need for this condition remains very high.
The global market of mitral valve replacement and repair is expected to grow at a rate of +35% per year between 2017 and 2020, and to reach $3.5 billion by 2022 (1)
(1) Azoth Analytics. Transcatheter Mitral Valve Repair and Replacement (TMVR) Market – Opportunities and forecast: 2017-22.